AstraZeneca resumes trials of COVID vaccine halted by patient illness AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after receiving the green light from safety watchdogs, the company said on Saturday. Michael Holden U.S.

LONDON (Reuters) - AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after receiving the green light from safety watchdogs, the company said on Saturday.

The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout.

“On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators,” AstraZeneca said.

It added that safety reviewers had recommended to Britain’s Medicines Health Regulatory Authority (MHRA) that it was safe to resume the UK trials.

The patient involved in the study had been reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

AstraZeneca, based in Cambridge, said it could not disclose further medical information. ...

Also see:

Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers

https://www.reuters.com/article/us-health-coronavirus-pfizer-biontech/pfizer-biontech-propose-expanding-covid-19-vaccine-trial-to-44000-volunteers-idUSKBN2630QH?il=0